Minnesota Academy of Family Physicians
MARCH 27, 2025
The Minnesota Council of Health Plans (MCHP) raised concerns, as the bill enacts new regulations on health plans, and they contend they have little control over pricing set by drug manufacturers. 2007 ( Representative Nadeau ) established a spoken language health care interpreter work group. Read a summary of H.F.
FDA Law Blog
SEPTEMBER 30, 2022
47 (2007), which addressed the intent standard under the Fair Credit Reporting Act. CMS itself has recognized this by repeatedly inviting manufacturers to use reasonable assumptions where a question is not addressed in the statute, regulations, or CMS guidance. of America v. Burr , 551 U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Health Policy Exchange
MAY 20, 2013
Food and Drug Administration to market a new drug is a critical waypoint along the path to profits for pharmaceutical manufacturers. In the meantime, lobbyists working for the drug manufacturers successfully blocked efforts by Medicare administrators to stop paying for the higher (harmful) doses. Approval from the U.S.
CDOCS
MARCH 15, 2021
important;" xml:lang="EN-US">In 2007, a few of us were sitting at dinner when the CEO of our company at the time, Mr. Imtiaz Manji, came up with an idea for the cerecdoctors.com Magazine. Sometimes, however, it’s difficult to leave the old ways behind.&
FDA Law Blog
MAY 11, 2023
Specifically, the Government explained, “[t]he section viii pathway cannot function properly if FDA and generic manufacturers cannot rely on an NDA holder’s representations to the agency regarding which portions of the brand-name drug’s labeling teach patented methods of use.”
FDA Law Blog
AUGUST 21, 2023
FDA did, however, try to identify safety issues through the medical literature and (after 2007 when mandatory safety reporting for OTC human drug products marketed without an approved application became effective) through the adverse event reporting system. Koblitz & Deborah L. More than a few have taken far longer—literally decades.
FDA Law Blog
FEBRUARY 4, 2025
The authors suggested that the developers of such therapies would receive a priority review voucher that they can sell to manufacturers of blockbuster drugs. This time, however, the program, which has helped incentivize the development of dozens of pediatric rare disease therapies since 2012, was not renewed.
Expert insights. Personalized for you.
52 
Let's personalize your content